SIGA
SIGA Technologies·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
MACD Death Cross
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SIGA
Siga Technologies, Inc.
A commercial-stage pharmaceutical company focused on the health security market
31 East 62nd Street, New York, NY 10065
--
SIGA Technologies, Inc., is incorporated in Delaware. The company is a commercial-stage pharmaceutical company. The company sells its main product TPOXX to the US government and international governments. In addition, the company sells intravenous preparations of TPOXX to the US government. TPOXX is an oral antiviral drug used to treat human smallpox disease caused by smallpox virus. About IV TPOXX, SIGA Technologies, Inc., announced on May 19, 2022 that the FDA approved the formulation for the treatment of smallpox. In addition to FDA approval, oral TPOXX has regulatory approval from the European Medicines Agency, Health Canada and the UK Medicines and Healthcare Products Regulatory Agency.
Earnings Call
Q2/2025
Estimate EPS--
Actual EPS0.49
Estimate Revenue--
Actual Revenue79.10M
SIGA Technologies' Q2 2025: Navigating Contradictions in RFP Timelines, Dividend Policies, and Product Delivery
Aug 06,2025 02:09
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS--
Actual EPS-0.01
Estimate Revenue--
Actual Revenue7.00M
SIGA's Q1 2025: Key Contradictions in Government Contracts, Dividends, and Policy Impacts
May 19,2025 09:33
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SIGA has released its 2025 Q3 earnings. EPS was reported at -0.09, versus the expected 0, missing expectations. The chart below visualizes how SIGA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SIGA has released its 2025 Q2 earnings report, with revenue of 81.12M, reflecting a YoY change of 271.92%, and net profit of 35.48M, showing a YoY change of 1836.20%. The Sankey diagram below clearly presents SIGA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
